Biogen Inc
NASDAQ: BIIB
$197.60
-$1.76 (-0.9%)
Real Time Data Delayed 15 Min.
BIIB Articles
Below are some of the top analyst calls we are seeing from Wall Street firms this Thursday morning: Biogen Idec (BIIB) Raised to Buy at Lazard. Cowen (COWN) Raised to Outperform at KBW. Mylan Labs...
Published:
These are some of the early bird analyst upgrades and positive calls we are seeing this Thursday morning with more than two hours to the open: Auxilium Pharma (AUXL) Started as Outperform at...
Published:
Icahn Enterprises LP (NYSE: IEP) is perhaps known more for its billionaire owner/founder Carl Icahn more than it is for its staff, team efforts, and even the enterprise’s name. Icahn’s...
Published:
Last Updated:
These are some of the key analyst downgrades and negative analyst calls we have seen early this Monday morning with over 2 hours to open: Biogen Idec (BIIB) Cut to Sell at Banc of America. Cbeyond...
Published:
Carl Icahn has evolved over the years, first rising to fame a "corporate raider", followed by an ill-fated journey into actual management at the helm of TWA and, most recently, as a kinder, gentler...
Published:
Last Updated:
Elan Corporation (ELN) Problems with one of the company’s major drugs. Falls to $9.55 from 52-week high of $37.45. Gatehouse (GHS) More poor newspaper earnings raise issue of whether company is...
Published:
Last Updated:
This morning’s share price reaction seen in Biogen-Idec Inc. (NASDAQ: BIIB) and Elan Corp. plc (NYSE: ELN) is severe. We do not want to try to sound as though this TYSABRI news is something that...
Published:
Last Updated:
Genentech Inc. (NYSE: DNA) is set to report earnings after the close of trading today. The largest biotech in the U.S. is expected to post $0.86 EPS on $3.23 Billion in revenues according to First...
Published:
There was interesting event in a 13D filing today right after the close, and that will be worth some news and gossip alike. An investment firm called Amalgamated Gadget LP, which is roughly a 6.6%...
Published:
Last Updated:
Carl Icahn is a billionaire financier, activist, and investor. Most think of Icahn as an activist investor that wants to get inside and drive value without having to acquire the whole company to...
Published:
Last Updated:
Genentech, Inc. (NYSE:DNA) and Biogen Idec, Inc. (Nasdaq:BIIB) came out this morning with some disappointing news. The biotech giants have announced that a Phase II/III study of Rituxan for lupus...
Published:
Biogen Idec (NASDAQ: BIIB) is sliding marginally despite reported earnings today that showed a 23% increase in earnings riding on sales growth on Avonex and Rituxan. The earnings beat estimates and...
Published:
Thursday after the close, we’ll get to see earnings out of Genentech (NASDAQ: DNA). The estimates from First Call are $0.82 EPS on $3.11 billion in revenues. Next quarter estimates are $0.86 EPS...
Published:
Many biotech stocks are enjoying large gains Monday, although some are on no real breaking news. Here is a look at some notable gainers: Amylin Pharmaceuticals Inc. (NASDAQ: AMLN) up $1.39 to $28.97,...
Published:
Billionaire activist investor and financier Carl Icahn has released the total holdings in an SEC filing for the period end December 31, 2007 for ICAHN CAPITAL, LP. As Carl Icahn and his friends are...
Published:
Last Updated: